ZELSUVMI revenue jumped 45% as prescriber count surged and new PBM contracts drove adoption. CEO O'Dowd eyes 5% stake as company targets $3.2 million in annual savings. Key points and original sources are listed below.

• ZELSUVMI revenue jumped 45% as prescriber count surged and new PBM contracts drove adoption.S1

• CEO O'Dowd eyes 5% stake as company targets $3.2 million in annual savings.S2

• Dolphin Entertainment (DLPN) Q2 2026 Earnings Call TranscriptS3

• Recurring revenue surged 14% as management targets adjusted EBITDA profitability by year-end.S4

• Record backlog of $3.8 billion supports stronger earnings visibility ahead.S5

• Financing package of $100M extends cash runway to Q3 2027 amid certification delay.S6

• EscharEx advances Phase III enrollment while manufacturing facility nears regulatory completion.S7

• Northern Star Resources Limited (NESRF) Q4 2026 Earnings Call TranscriptS8